Who will finance early stage drug discovery?

Biotech companies looking for financing or new assets. Pharma and sponsors are looking for new assets to plug into their research and development pipeline. Where to source innovation from and how to fund that innovation is one of the biggest questions around.

This March at BioEurope Spring, Susan Schaeffer, the Editor, at BioCentury will be hosting the panel Who will finance early stage drug discovery? with participants Jason Coloma the Global Head, Venture and Innovation at Roche Partnering and Ilka Wicke, the Director, Investment Manager of the Boehringer-Ingelheim Venture Fund at Boehringer Ingelheim. Common wisdom holds that it is getting harder and harder to find funding for drug discovery—yet financing data show that private rounds for companies whose lead programs are in preclinical development and earlier have been steadily rising since the meltdown. On top of that, big pharma is increasingly partnering directly with academics on discovery research, as well as participating in regional incubators that support early stage startups.

Would you like to join the conversation?  Join us at BioEurope Spring talking place this March 10-12 in Turin, Italy.  For more information on the program and partnering opportunities, visit the webpage.  Start the conversation early by joining our BioEurope Spring Group on partnershing360.